Table 1

Cost-effectiveness per person invited for screening of FIT versus gFOBT by FIT threshold compared with gFOBT

Incremental total cost compared with gFOBT, mean (£) (95% CI)Incremental life years compared with gFOBT, mean (95% CI)Incremental QALYs compared with gFOBT, mean (95% CI)ICER: incremental cost per QALY gained compared with gFOBT (£)*Incremental net benefit compared with gFOBT, mean (£) (95% CI)**
FIT 180 µg Hb/g faeces (base case)−27 (−43 to -12)0.019 (0.016 to 0.023)0.014 (0.012 to 0.017)FIT dominates (p<0.001)315 (256 to 377)
FIT 150 µg Hb/g faeces−40 (−62 to -19)0.028 (0.024 to 0.032)0.021 (0.018 to 0.024)FIT dominates (p<0.001)458 (388 to 531)
FIT 100 µg Hb/g faeces−53 (−86 to -23)0.038 (0.033 to 0.043)0.029 (0.025 to 0.033)FIT dominates (p<0.001)637 (546 to 731)
FIT 40 µg Hb/g faeces−84 (−151 to -24)0.073 (0.065 to 0.082)0.058 (0.051 to 0.064)FIT dominates (p<0.005)1237 (1072 to 1405)
FIT 20 µg Hb/g faeces−62 (−141 to 8)0.082 (0.072 to 0.091)0.066 (0.057 to 0.074)FIT dominates (p<0.050)1378 (1177 to 1582)
  • Means are deterministic means; all 95% CIs calculated as percentiles of 1000 probabilistic model runs.

  • *Incremental cost-effectiveness ratio (ICER)=ΔC/ΔE, where ΔE and ΔC are the incremental QALYs and incremental costs, respectively, of FIT compared with gFOBT. p -values calculated as the proportion of the 1000 PSA simulations with positive ICERs.

  • **INB= λ.ΔE – ΔC, where λ is the willingness to pay threshold=£20 000 per QALY gained.

  • FIT, faecal immunochemical test; gFOBT, guaiac faecal occult blood test; QALY, quality-adjusted life years.